Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H10ClN3O4S2 |
| Molecular Weight | 371.819 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(C(=O)NC2=CC=CC=N2)=C(O)C3=C(C=C(Cl)S3)S1(=O)=O
InChI
InChIKey=WLHQHAUOOXYABV-UHFFFAOYSA-N
InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19)
| Molecular Formula | C13H10ClN3O4S2 |
| Molecular Weight | 371.819 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Xefo_30/WC500009083.pdfCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB06725
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Xefo_30/WC500009083.pdf
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB06725
Lornoxicam (Xefo®) is a nonsteroidal anti-inflammatory drug of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. It differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. The inhibition of the cyclooxygenase enzymes (COX-1 and COX-2) by lornoxicam (Xefo®) leads to desensitisation of peripheral nociceptors and consequently inhibition of inflammation. A central effect on nociception which seems to be independent of anti-inflammatory effects has also been suggested.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL221 |
0.003 µM [IC50] | ||
Target ID: CHEMBL230 |
0.008 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | XEFO Approved UseShort-term relief of acute mild to moderate pain.
Symptomatic relief of pain and inflammation in osteoarthritis.
Symptomatic relief of pain and inflammation in rheumatoid arthritis. |
|||
| Palliative | XEFO Approved UseShort-term relief of acute mild to moderate pain.
Symptomatic relief of pain and inflammation in osteoarthritis.
Symptomatic relief of pain and inflammation in rheumatoid arthritis. |
|||
| Palliative | XEFO Approved UseShort-term relief of acute mild to moderate pain.
Symptomatic relief of pain and inflammation in osteoarthritis.
Symptomatic relief of pain and inflammation in rheumatoid arthritis. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
210 ng/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
414 ng/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
931 ng/mL |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
591 ng/mL |
8 mg 3 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
687 ng/mL |
8 mg 3 times / day steady-state, oral dose: 8 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
353 ng/mL |
4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
276 ng/mL |
4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
301 ng/mL |
4 mg 2 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
756.17 ng/mL |
8 mg 2 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
742.33 ng/mL |
8 mg 2 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
867.33 ng/mL |
8 mg 2 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
787.42 ng/mL |
8 mg 2 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
696 ng/mL |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
554 ng/mL |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
587 ng/mL |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
210 ng/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
136 ng/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
601 ng × h/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1248 ng × h/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2645 ng × h/mL |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3349 ng × h/mL |
8 mg 3 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
6312 ng × h/mL |
8 mg 3 times / day steady-state, oral dose: 8 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1552 ng × h/mL |
4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
1338 ng × h/mL |
4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
1606 ng × h/mL |
4 mg 2 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3442.6 ng × h/mL |
8 mg 2 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3733.7 ng × h/mL |
8 mg 2 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3805.2 ng × h/mL |
8 mg 2 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3719.1 ng × h/mL |
8 mg 2 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3882 ng × h/mL |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
3148 ng × h/mL |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
4724 ng × h/mL |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
600.99 ng × h/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
546 ng × h/mL |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.41 h |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.3 h |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.83 h |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.27 h |
8 mg 3 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
5.27 h |
8 mg 3 times / day steady-state, oral dose: 8 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
154 min |
4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
154 min |
4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
3.36 h |
8 mg 2 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.85 h |
8 mg 2 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.86 h |
8 mg 2 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.37 h |
8 mg 2 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.4 h |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
5.1 h |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
4.3 h |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
2.41 h |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.16 h |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORNOXICAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.38% |
4 mg 2 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LORNOXICAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
0.65% |
LORNOXICAM serum | Homo sapiens |
Doses
| Dose | Population | Adverse events |
|---|---|---|
32 mg single, oral Highest studied dose |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
8 mg 2 times / day multiple, oral Recommended Dose: 8 mg, 2 times / day Route: oral Route: multiple Dose: 8 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Upper abdominal pain... AEs leading to discontinuation/dose reduction: Upper abdominal pain (0.9%) Sources: |
8 mg 2 times / day multiple, oral Recommended Dose: 8 mg, 2 times / day Route: oral Route: multiple Dose: 8 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Dizziness, Diarrhoea... AEs leading to discontinuation/dose reduction: Dizziness (0.16%) Sources: Diarrhoea (0.16%) Vomiting (0.16%) Itching (0.1%) Urticaria (0.1%) Haematoma (0.05%) Stridor (0.05%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Upper abdominal pain | 0.9% Disc. AE |
8 mg 2 times / day multiple, oral Recommended Dose: 8 mg, 2 times / day Route: oral Route: multiple Dose: 8 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Haematoma | 0.05% Disc. AE |
8 mg 2 times / day multiple, oral Recommended Dose: 8 mg, 2 times / day Route: oral Route: multiple Dose: 8 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Stridor | 0.05% Disc. AE |
8 mg 2 times / day multiple, oral Recommended Dose: 8 mg, 2 times / day Route: oral Route: multiple Dose: 8 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Itching | 0.1% Disc. AE |
8 mg 2 times / day multiple, oral Recommended Dose: 8 mg, 2 times / day Route: oral Route: multiple Dose: 8 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Urticaria | 0.1% Disc. AE |
8 mg 2 times / day multiple, oral Recommended Dose: 8 mg, 2 times / day Route: oral Route: multiple Dose: 8 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Diarrhoea | 0.16% Disc. AE |
8 mg 2 times / day multiple, oral Recommended Dose: 8 mg, 2 times / day Route: oral Route: multiple Dose: 8 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Dizziness | 0.16% Disc. AE |
8 mg 2 times / day multiple, oral Recommended Dose: 8 mg, 2 times / day Route: oral Route: multiple Dose: 8 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Vomiting | 0.16% Disc. AE |
8 mg 2 times / day multiple, oral Recommended Dose: 8 mg, 2 times / day Route: oral Route: multiple Dose: 8 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis. | 2014 |
|
| Toxicogenomic biomarkers for renal papillary injury in rats. | 2013-01-07 |
|
| Analgesic effects of lornoxicam after total abdominal hysterectomy. | 2007-11-22 |
|
| Analgesic efficacy and safety of lornoxicam quick-release formulation compared with diclofenac potassium: randomised, double-blind trial in acute low back pain. | 2006 |
|
| Lornoxicam, a new potent NSAID with an improved tolerability profile. | 2000-01 |
|
| Efficacy and tolerability of lornoxicam versus tramadol in postoperative pain. | 1999-08 |
|
| The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. | 1999-07 |
|
| Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. | 1998-06 |
|
| Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. | 1996-04 |
|
| Introduction: mechanism of action of NSAIDs. | 1996-04 |
|
| Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. | 1996 |
|
| Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. | 1994-02 |
|
| Pharmacokinetics of lornoxicam in man. | 1990 |
|
| Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. | 1990 |
Patents
Sample Use Guides
Pain:
8-16 mg lornoxicam (Xefo®) daily divided into 2 or 3 doses. Maximum recommended daily dose is 16 mg.
Osteoarthritis and Rheumatoid arthritis:
Initial recommended dose is 12 mg lornoxicam (Xefo®) daily divided into 2 or 3 doses. Maintenance dose should not exceed 16 mg lornoxicam daily.
Route of Administration:
Oral
In HEL/Mono Mac 6 human cells, lornoxicam showed a balanced inhibition of COX-1/-2 exhibiting the lowest IC50 (0.003 microM/0.008 microM) of the large panel of non steroidal antiinflammatory drugs tested. Similar results were obtained in the whole blood for COX-1/-2 (IC50 values of 0.13 microM for both isoenzymes). NO formation was dose-dependently inhibited by lornoxicam (IC50 of 65 microM) whereas piroxicam, diclofenac, ibuprofen, ketorolac and naproxen inhibited the NO formation markedly less. In stimulated human monocytic cells (THP-1), lornoxicam showed a marked inhibition of IL-6 formation (IC50 54 microM) while the formation ofTNF-alpha, IL-1beta and IL-8 was only moderately affected.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:46:30 GMT 2025
by
admin
on
Mon Mar 31 17:46:30 GMT 2025
|
| Record UNII |
ER09126G7A
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QM01AC05
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
||
|
WHO-ATC |
M01AC05
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C059451
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
ER09126G7A
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
m6910
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | Merck Index | ||
|
BB-58
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
6233
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
CHEMBL1569487
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
1609
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
31783
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
20890
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | RxNorm | ||
|
Lornoxicam
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
759620
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
54690031
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
70374-39-9
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
100000090751
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
DTXSID6046133
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
DB06725
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
C72140
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY | |||
|
SUB08589MIG
Created by
admin on Mon Mar 31 17:46:30 GMT 2025 , Edited by admin on Mon Mar 31 17:46:30 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
